Preliminary data on infant exposure to lenacapavir during breastfeeding is minimal.[1] Achieving and maintaining viral suppression with antiretroviral therapy decreases breastfeeding transmission risk to less than 1%, but not zero. Individuals with HIV who are on antiretroviral therapy with a sustained undetectable viral load and who choose to breastfeed should be supported in this decision. If a viral load is not suppressed, banked pasteurized donor milk or formula is recommended.[2,3] Extended postnatal prophylaxis of breastfed infants with lenacapavir should continue until breastfeeding is stopped.[4]